Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13536909 | 0.91 | PKM (0.70) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL1932281 | 0.90 | PKM (0.65) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL2741402 | 0.89 | PKM (0.64) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL258778 | 0.87 | PKM (0.66) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL13625328 | 0.85 | PKM (0.72) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL28160480 | 0.83 | AKR1C3 (0.51) | HTTALDH1A1TSHRLMNAAKR1C3 | |
| SCHEMBL5915291 | 0.83 | KMT2A (0.56) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL14628174 | 0.82 | AKR1C3 (0.66) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL295028 | 0.80 | PKM (0.70) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL21207291 | 0.80 | LMNA (0.62) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930696-A | Imidazole coordinated ruthenium carbene olefin metathesis catalyst, preparation and application thereof | 中国石油天然气股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2025-02-06 | — | — | US | disclosed |
| EP-4433451-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | Ecole Nationale Supérieure de Chimie de Rennes (FR) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023088919-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES (FR) | 2023-05-25 | — | — | WO | disclosed |
| CN-112479984-B | Method for synthesizing enol trifluoromethanesulfonate | 湖北航天化学技术研究所 | 2022-12-13 | — | — | CN | disclosed |
| EP-3864021-A1 | COMPOSITIONS AND METHODS FOR VISIBLE-LIGHT-CONTROLLED RUTHENIUM-CATALYZED OLEFIN METATHESIS | The Trustees of Columbia University in the City of New York (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-108654695-B | Indole [3,2-a ] oxazolidine-labeled ruthenium carbene catalyst, and preparation method and application thereof | 天津大学 | 2021-04-06 | — | — | CN | disclosed |
| CN-108440230-A | The preparation method of alkene and the method for synthesizing ChondriamideA and ChondriamideC | 中国科学技术大学 | 2018-08-24 | — | — | CN | disclosed |
| US-9988339-B2 | Nonpolar phase-soluble metathesis catalysts | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180065914-A1 | RUTHENIUM POLYMERISATION CATALYSTS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-03-08 | — | — | US | disclosed |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2010-05-06 | — | — | US | disclosed |
| US-20090203860-A1 | Nonpolar phase-soluble methathesis catalysts | NATIONAL SCIENCE FOUNDATION | 2009-08-13 | — | — | US | disclosed |
| US-20090203860-A1 | Nonpolar phase-soluble methathesis catalysts | NATIONAL SCIENCE FOUNDATION | 2009-08-13 | — | — | US | disclosed |
| WO-2009009597-A1 | WATER SOLUBLE OLEFIN METATHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7348290-B2 | Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-03-25 | — | — | US | disclosed |
| US-7348290-B2 | Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20050119416-A1 | Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-06-02 | — | — | US | disclosed |
| US-4642348-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-02-10 | — | — | US | disclosed |
| US-4593102-A | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119416-A1 | Ring-opening or closing metathesis reaction of olefin; reduction of carbonyl compound, catalysis, complexing; cyclization, reduction | AOX1, AOC2, POR | PKM 1962/4885HTT 4455/4885ALDH1A1 2052/4885 |
| US-20090203860-A1 | Nonpolar phase-soluble methathesis catalysts | MMAB, HMBS, PEAK1 | PKM 1039/4885HTT 14/4885ALDH1A1 3476/4885 |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | SQLE, SYMPK, FDFT1 | PKM 4697/4885HTT 2939/4885ALDH1A1 1256/4885 |
| US-20180065914-A1 | RUTHENIUM POLYMERISATION CATALYSTS | RRP12, PCBP1, PARG | PKM 273/4885HTT 2876/4885ALDH1A1 4132/4885 |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | PKM 2892/4885HTT 3384/4885ALDH1A1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.